Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease. Matthew is also a pioneering international leader in the field of exosome biology, publishing in Nature Biotechnology in 2011 the landmark discovery that exosomes could be developed into a therapeutic drug modality. Matthew has continued his pioneering work in the exosome field and is one of the co-founders of Evox Therapeutics. Matthew is also a world expert in the field of oligonucleotide therapies and co-leads a major international translational medicine collaboration (MDEX Consortium) that helped develop eteplirsen, the first-ever treatment for Duchenne muscular dystrophy. Matthew is a Director of Oxford University’s technology transfer organisation (Oxford University Innovation) and is also a Founder and Director of PepGen Ltd., an Oxford-based start-up biotech company. He also serves on the Scientific Advisory Board of Sarepta Therapeutics. Matthew graduated in Medicine from the University of Cape Town, working in clinical neuroscience before gaining a doctorate in Physiological Sciences from Oxford University.